Toward personalized medicine: Using cardiomyocytes differentiated from urine-derived pluripotent stem cells to recapitulate electrophysiological characteristics of type 2 long QT syndrome

Journal of the American Heart Association

Volumn 4, Issue 9, 2015, Pages

  Jouni, Mariam ^a,b,c,d   Si Tayeb, Karim ^a,b,c   Es Salah Lamoureux, Zeineb ^a,b,c   Latypova, Xenia ^a,b,c   Champon, Benoite ^a,b,c   Caillaud, Amandine ^a,b,c   Rungoat, Anais ^a,b,c   Charpentier, Flavien ^a,b,c   Loussouarn, Gildas ^a,b,c   Baró, Isabelle ^a,b,c   Zibara, Kazem ^a,d   Lemarchand, Patricia ^a,b,c   Gaborit, Nathalie ^a,b,c  

^a L INSTITUT DU THORAX   (France)

^b CNRS   (France)

^c UNIVERSITÉ DE NANTES   (France)

^d LEBANESE UNIVERSITY   (Lebanon)

Author keywords

Arrhythmia; Cardiomyocytes; HERG gene; Long QT syndrome; Urine derived induced pluripotent stem cells

Indexed keywords

POTASSIUM CHANNEL; KCNH2 PROTEIN, HUMAN; POTASSIUM CHANNEL HERG;

ACTION POTENTIAL; ADULT; ARTICLE; CARDIAC MUSCLE CELL; CELL DIFFERENTIATION; CELL MIGRATION; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE; GENE MUTATION; HEART ARRHYTHMIA; HEART ELECTROPHYSIOLOGY; HERG GENE; HUMAN; HUMAN CELL; IN VITRO STUDY; KCNH2 GENE; LONG QT SYNDROME 2; MALE; MYOFILAMENT; PERSONALIZED MEDICINE; PHENOTYPE; PLURIPOTENT STEM CELL; POTASSIUM CURRENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; URINE DERIVED HUMAN INDUCED PLURIPOTENT STEM CELL; CELL CULTURE; CELL CULTURE TECHNIQUE; CELL REPROGRAMMING TECHNIQUE; CYTOLOGY; ELECTROCARDIOGRAPHY; GENETIC PREDISPOSITION; GENETICS; HIGH THROUGHPUT SCREENING; LONG QT SYNDROME; METABOLISM; MIDDLE AGED; MISSENSE MUTATION; PATCH CLAMP TECHNIQUE; PATHOLOGY; PROCEDURES; URINE; VALIDATION STUDY; YOUNG ADULT;

ACTION POTENTIALS; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELLS, CULTURED; CELLULAR REPROGRAMMING TECHNIQUES; ELECTROCARDIOGRAPHY; ERG1 POTASSIUM CHANNEL; ETHER-A-GO-GO POTASSIUM CHANNELS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; MUTATION, MISSENSE; MYOCYTES, CARDIAC; PATCH-CLAMP TECHNIQUES; PHENOTYPE; PLURIPOTENT STEM CELLS; PRECISION MEDICINE; URINE; YOUNG ADULT;

EID: 85006201984     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.115.002159     Document Type: Article

References (35)

1. Zanella F, Lyon RC, Sheikh F. Modeling heart disease in a dish: from somatic cells to disease-relevant cardiomyocytes. Trends Cardiovasc Med. 2014;24:32-44.
2. Inoue H, Nagata N, Kurokawa H, Yamanaka S. Ips cells: a game changer for future medicine. EMBO J. 2014;33:409-417.
3. Zhou T, Benda C, Dunzinger S, Huang Y, Ho JC, Yang J, Wang Y, Zhang Y, Zhuang Q, Li Y, Bao X, Tse HF, Grillari J, Grillari-Voglauer R, Pei D, Esteban MA. Generation of human induced pluripotent stem cells from urine samples. Nat Protoc. 2012;7:2080-2089.
4. Xue Y, Cai X, Wang L, Liao B, Zhang H, Shan Y, Chen Q, Zhou T, Li X, Hou J, Chen S, Luo R, Qin D, Pei D, Pan G. Generating a non-integrating human induced pluripotent stem cell bank from urine-derived cells. PLoS One. 2013;8:e70573.
5. Lee KI, Kim HT, Hwang DY. Footprint- and xeno-free human ipscs derived from urine cells using extracellular matrix-based culture conditions. Biomaterials. 2014;35:8330-8338.
6. Gerbal-Chaloin S, Funakoshi N, Caillaud A, Gondeau C, Champon B, Si-Tayeb K. Human induced pluripotent stem cells in hepatology: beyond the proof of concept. Am J Pathol. 2014;184:332-347.
7. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, Yamanaka S. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861-872.
8. Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, Okita K, Mochiduki Y, Takizawa N, Yamanaka S. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol. 2008;26:101-106.
9. Zhang Z, Gao Y, Gordon A, Wang ZZ, Qian Z, Wu WS. Efficient generation of fully reprogrammed human ips cells via polycistronic retroviral vector and a new cocktail of chemical compounds. PLoS ONE. 2011;6:e26592.
10. Yu J, Chau KF, Vodyanik MA, Jiang J, Jiang Y. Efficient feeder-free episomal reprogramming with small molecules. PLoS ONE. 2011;6:e17557.
11. Okita K, Yamanaka S. Induced pluripotent stem cells: opportunities and challenges. Philos Trans R Soc Lond B Biol Sci. 2011;366:2198-2207.
12. Guan X, Mack DL, Moreno CM, Strande JL, Mathieu J, Shi Y, Markert CD, Wang Z, Liu G, Lawlor MW, Moorefield EC, Jones TN, Fugate JA, Furth ME, Murry CE, Ruohola-Baker H, Zhang Y, Santana LF, Childers MK. Dystrophin-deficient cardiomyocytes derived from human urine: new biologic reagents for drug discovery. Stem Cell Res. 2014;12:467-480.
13. Muller M, Seufferlein T, Illing A, Homann J. Modelling human channelopathies using induced pluripotent stem cells: a comprehensive review. Stem Cells Int. 2013;2013:496501.
14. Bellocq C, Wilders R, Schott JJ, Louerat-Oriou B, Boisseau P, Le Marec H, Escande D, Baro I. A common antitussive drug, clobutinol, precipitates the long qt syndrome 2. Mol Pharmacol. 2004;66:1093-1102.
15. Si-Tayeb K, Noto FK, Nagaoka M, Li J, Battle MA, Duris C, North PE, Dalton S, Duncan SA. Highly efficient generation of human hepatocyte-like cells from induced pluripotent stem cells. Hepatology. 2010;51:297-305.
16. Zhang J, Klos M, Wilson GF, Herman AM, Lian X, Raval KK, Barron MR, Hou L, Soerens AG, Yu J, Palecek SP, Lyons GE, Thomson JA, Herron TJ, Jalife J, Kamp TJ. Extracellular matrix promotes highly efficient cardiac differentiation of human pluripotent stem cells: the matrix sandwich method. Circ Res. 2012;111:1125-1136.
17. Terrenoire C, Wang K, Tung KW, Chung WK, Pass RH, Lu JT, Jean JC, Omari A, Sampson KJ, Kotton DN, Keller G, Kass RS. Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics. J Gen Physiol. 2013;141:61-72.
18. Rivero-Gutierrez B, Anzola A, Martinez-Augustin O, de Medina FS. Stain-free detection as loading control alternative to ponceau and housekeeping protein immunodetection in western blotting. Anal Biochem. 2014;467:1-3.
19. Gurtler A, Kunz N, Gomolka M, Hornhardt S, Friedl AA, McDonald K, Kohn JE, Posch A. Stain-free technology as a normalization tool in western blot analysis. Anal Biochem. 2013;433:105-111.
20. Loussouarn G, Baro I, Escande D. KCNQ1K+ channel-mediated cardiac channelopathies. Methods Mol Biol. 2006;337:167-183.
21. Bellin M, Casini S, Davis RP, D'Aniello C, Haas J, Ward-van Oostwaard D, Tertoolen LG, Jung CB, Elliott DA, Welling A, Laugwitz KL, Moretti A, Mummery CL. Isogenic human pluripotent stem cell pairs reveal the role of a KCNH2 mutation in long-QT syndrome. EMBO J. 2013;32:3161-3175.
22. Zhang J, Wilson GF, Soerens AG, Koonce CH, Yu J, Palecek SP, Thomson JA, Kamp TJ. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res. 2009;104:e30-e41.
23. Sepac A, Si-Tayeb K, Sedlic F, Barrett S, Canfield S, Duncan SA, Bosnjak ZJ, Lough JW. Comparison of cardiomyogenic potential among human ESC and IPSC lines. Cell Transplant. 2012;21:2523-2530.
24. Zhou Z, Gong Q, Ye B, Fan Z, Makielski JC, Robertson GA, January CT. Properties of herg channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys J. 1998;74:230-241.
25. Clancy CE, Rudy Y. Cellular consequences of herg mutations in the long QT syndrome: precursors to sudden cardiac death. Cardiovasc Res. 2001;50:301-313.
26. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663-676.
27. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, Nie J, Jonsdottir GA, Ruotti V, Stewart R, Slukvin II, Thomson JA. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318:1917-1920.
28. Priori SG, Napolitano C, Di Pasquale E, Condorelli G. Induced pluripotent stem cell-derived cardiomyocytes in studies of inherited arrhythmias. J Clin Invest. 2013;123:84-91.
29. Matsa E, Rajamohan D, Dick E, Young L, Mellor I, Staniforth A, Denning C. Drug evaluation in cardiomyocytes derived from human induced pluripotent stem cells carrying a long QT syndrome type 2 mutation. Eur Heart J. 2011;32:952-962.
30. Itzhaki I, Maizels L, Huber I, Zwi-Dantsis L, Caspi O, Winterstern A, Feldman O, Gepstein A, Arbel G, Hammerman H, Boulos M, Gepstein L. Modelling the long QT syndrome with induced pluripotent stem cells. Nature. 2011;471:225-229.
31. Lahti AL, Kujala VJ, Chapman H, Koivisto AP, Pekkanen-Mattila M, Kerkela E, Hyttinen J, Kontula K, Swan H, Conklin BR, Yamanaka S, Silvennoinen O, Aalto-Setala K. Model for long QT syndrome type 2 using human IPS cells demonstrates arrhythmogenic characteristics in cell culture. Dis Model Mech. 2012;5:220-230.
32. Mehta A, Sequiera GL, Ramachandra CJ, Sudibyo Y, Chung Y, Sheng J, Wong KY, Tan TH, Wong P, Liew R, Shim W. Re-trafficking of herg reverses long QT syndrome 2 phenotype in human IPS-derived cardiomyocytes. Cardiovasc Res. 2014;102:497-506.
33. Ye L, Zhang S, Greder L, Dutton J, Keirstead SA, Lepley M, Zhang L, Kaufman D, Zhang J. Effective cardiac myocyte differentiation of human induced pluripotent stem cells requires vegf. PLoS ONE. 2013;8:e53764.
34. Marjamaa A, Salomaa V, Newton-Cheh C, Porthan K, Reunanen A, Karanko H, Jula A, Lahermo P, Vaananen H, Toivonen L, Swan H, Viitasalo M, Nieminen MS, Peltonen L, Oikarinen L, Palotie A, Kontula K. High prevalence of four long QT syndrome founder mutations in the finnish population. Ann Med. 2009;41:234-240.
35. Moss AJ, Zareba W, Kaufman ES, Gartman E, Peterson DR, Benhorin J, Towbin JA, Keating MT, Priori SG, Schwartz PJ, Vincent GM, Robinson JL, Andrews ML, Feng C, Hall WJ, Medina A, Zhang L, Wang Z. Increased risk of arrhythmic events in long-QT syndrome with mutations in the pore region of the human ether-a-go-gorelated gene potassium channel. Circulation. 2002;105:794-799.